PRNewswire: March 21, 2017 – NEW YORK, NY, U.S.A. and SYDNEY, Australia – EnGeneIC Limited today announced that it has begun dosing patients in a U.S.-based open-label phase 1 clinical trial evaluating its proprietary EDV™ nanocells to treat recurrent glioblastoma multiforme (GBM) in adults.
GBM…
